In a proportional hazard analysis performed in another study, we found that the application of the VNR + DIF combination but not platinum-based chemotherapy was a significant and independent factor to prolong survival in lung adenocarcinoma patients with EGFR mutations (unpublished data). This evidence concerns the gene EGFR and lung adenocarcinoma.